COGTCogent Biosciences, Inc.

Nasdaq cogentbio.com


$ 7.62 $ -0.16 (-2.06 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 7.6
$ 7.57
$ 0.00 x 0
$ 0.00 x 0
$ 7.42 - $ 7.82
$ 3.67 - $ 13.50
1,299,194
na
720.52M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-26-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-28-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-cogent-biosciences-maintains-18-price-target

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

 cogent-biosciences-q1-eps-062-misses-051-estimate

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of ...

 marinus-pharmaceuticals-neumora-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

 jp-morgan-maintains-overweight-on-cogent-biosciences-raises-price-target-to-20

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...

 citigroup-maintains-buy-on-cogent-biosciences-raises-price-target-to-13

Citigroup analyst David Lebowitz maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $11 ...

 cogent-biosciences-q4-eps-063-down-from-056-yoy

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.63) per share. This is a 12.5 percent decrease over losses of...

 needham-reiterates-buy-on-cogent-biosciences-maintains-18-price-target

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

 wedbush-maintains-neutral-on-cogent-biosciences-raises-price-target-to-10

Wedbush analyst David Nierengarten maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target fro...

 cogent-biosciences-announces-part-1b-data-from-summit-trial-evaluating-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-51-week-12-mean-change-in-total-symptom-score-including-70-of-patients-achieving-50-reduction-in-tss-at-week-12

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily o...

 why-sony-shares-are-trading-lower-by-around-6-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financi...

 needham-reiterates-buy-on-cogent-biosciences-maintains-15-price-target

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $15 price target.

 citigroup-initiates-coverage-on-cogent-biosciences-with-buy-rating-announces-price-target-of-11

Citigroup analyst David Lebowitz initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Buy rating and announces Pric...

 cogent-biosciences-announces-planned-2024-milestones-for-bezuclastinib-emerging-portfolio-of-selective-and-potent-targeted-therapeutics

Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; pres...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION